Try our beta test site
57 studies found for:    acute myelomonocytic leukemia | Open Studies
Show Display Options
Rank Status Study
21 Not yet recruiting WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions: Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome With Isolated Del(5q);   Myelodysplastic/Myeloproliferative Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Cytarabine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: WEE1 Inhibitor AZD1775
22 Recruiting Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia
Interventions: Other: Antitumor Drug Screening Assay;   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Other: Pharmacological Study;   Drug: Ponatinib Hydrochloride;   Drug: Sorafenib Tosylate;   Drug: Sunitinib Malate
23 Recruiting Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia-2;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Drug: Idarubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Pomalidomide
24 Recruiting The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
Intervention:
25 Recruiting Study of Lenzilumab (KB003) in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)
Condition: Chronic Myelomonocytic Leukemia (CMML)
Intervention: Drug: lenzilumab
26 Recruiting Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
Conditions: Acute Myelogenous Leukemia;   Acute Lymphoid Leukemia;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: azacitidine;   Biological: donor lymphocyte infusion
27 Recruiting Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Secondary Acute Myeloid Leukemia
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Biological: Indium In 111 Anti-CD45 Monoclonal Antibody BC8;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Radiation: Total-Body Irradiation;   Radiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
28 Recruiting Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   CD45-Positive Neoplastic Cells Present;   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Radiation: Iodine I 131 Monoclonal Antibody BC8;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
29 Not yet recruiting Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Myeloproliferative Neoplasm;   Chronic Myelomonocytic Leukemia
Interventions: Drug: APR-246;   Drug: Azacitidine
30 Recruiting Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia
Condition: Leukemia, Myelomonocytic, Chronic
Intervention: Drug: Tipifarnib
31 Not yet recruiting A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)
Condition: Leukemia, Myelomonocytic, Chronic
Interventions: Drug: Cohort 1, Ceplene® and Proleukin®;   Drug: Cohort 2, Ceplene® and Proleukin®;   Drug: Cohort 3, Ceplene® and Proleukin®
32 Recruiting Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
Condition: Juvenile Myelomonocytic Leukemia
Interventions: Biological: Stem Cell Transplant;   Drug: Preparative Regimen
33 Recruiting Phase II Trial of Myeloablative Conditioning & Transplantation of Partially HLA-mismatched Marrow With Post-transplant Cyclophosphamide for Peds Pts w/ Hematologic Malignancies
Conditions: Myeloablative Conditioning;   HLA-mismatched Bone Marrow Transplantation;   Graft Survival;   Transplantion, Bone Marrow
Interventions: Drug: Cyclophosphamide;   Radiation: TBI;   Drug: Busulfan;   Other: Unmanipulated Bone Marrow;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
34 Recruiting Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
Conditions: Non-Hodgkin's Lymphoma;   Acute Leukemia in Remission;   Chronic Myeloid Leukemia;   Primary Myelofibrosis;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndromes;   Hodgkin Lymphoma;   Multiple Myeloma
Interventions: Drug: Fludarabine;   Drug: Busulfan;   Drug: Cyclophosphamide;   Radiation: Total body irradiation (TBI);   Procedure: Peripheral Blood Hematopoietic Cell Transplantation (HCT);   Drug: Sirolimus (SIR);   Drug: Mycophenolate mofetil (MMF);   Drug: Granulocyte-colony stimulating factor (G-CSF)
35 Recruiting Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
Conditions: Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes;   Chronic Myelogenous Leukemia;   Juvenile Myelomonocytic Leukemia;   Lymphoma,Non-Hodgkin;   Lymphoma, Hodgkin;   Lymphoma, Follicular;   Marginal Zone Lymphoma;   Large Cell Lymphoma;   Mantle-Cell Lymphoma;   Gray Zone Lymphoma;   Burkitt Lymphoma
Interventions: Drug: Bendamustine;   Drug: Cyclophosphamide
36 Recruiting Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
Conditions: AML;   CMML;   MDS
Intervention: Drug: FF-10501-01
37 Not yet recruiting Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)
Conditions: Acute Leukemias;   Chronic Leukemias;   Myelodysplastic Syndrome;   Juvenile Myelomonocytic Leukemia
Intervention: Drug: Busulfan/Cyclophosphamide
38 Recruiting Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Conditions: Acute Lymphoblastic Leukemia/Lymphoma;   Myelodysplasia;   Acute Myelogenous Leukemia;   Juvenile Myelomonocytic Leukemia;   Chronic Myelogenous Leukemia
Intervention:
39 Recruiting Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
Conditions: Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myeloid Sarcoma;   Chronic Myeloid Leukemia (CML);   Juvenile Myelomonocytic Leukemia (JMML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin Lymphoma (NHL)
Interventions: Drug: Anti-thymocyte globulin (rabbit);   Drug: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: G-CSF;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Drug: Tacrolimus;   Drug: Thiotepa;   Biological: HPC,A Infusion
40 Recruiting Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)
Conditions: Myelodysplastic Syndrome;   Leukemia, Myelomonocytic, Juvenile
Intervention: Drug: Azacitidine

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-57) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.